Asset profile
Sabirnetug
Monoclonal antibody
Evidence outlook · lead readout
NCT04931459 · Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04931459: The trial was randomized and blinded against placebo, but its main purpose was to check safety, tolerability and drug levels in early-phase dosing cohorts rather than to prove a clinical benefit. No results have been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.